NX 201 - Nalo Therapeutics
Alternative Names: NX-201 - Nalo TherapeuticsLatest Information Update: 29 Mar 2024
At a glance
- Originator Nalo Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-myc degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 04 Mar 2024 Preclinical trials in Cancer in USA (unspecified route) (Nalo Therapeutics pipeline, March 2024)
- 04 Mar 2024 Nalo Therapeutics plans clinical trial for Cancer (Nalo Therapeutics pipeline, March 2024)